MESOBLAST LIMITED
Panjang
Telah dikemas kini

MSB gets Fast Track from FDA

235
Looks like price is respecting trendline / uptrend.

Price is within range. Needs to break above resistance and stay above for bullish confirmation.

Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).

Overall lots of bullish news, Novartis partnership + FDA Fast Track for Remestemcell-L
Nota
Sadly bad news came out and the trend was invalidated - trading just above 78.6% area. I'm in quite a rough drawdown on my positions but you live and you learn. Biotcech stocks are highly risky!

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.